Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
MAPK pathway
gene targeting
histiocytosis
myeloproliferative disorder
targeted therapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
20
06
2023
received:
05
05
2023
accepted:
22
06
2023
pmc-release:
01
11
2024
medline:
1
11
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB-approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were interrupted after achieving complete or partial response by 18-fluorodeoxyglucose positron emission tomography (FDG-PET). 17/22 (77%) of patients experienced disease relapse following treatment interruption. Achieving a complete response prior to interruption, having a mutation other than BRAFV600E, and receiving MEK inhibition only were each associated with a statistically significant improvement in relapse-free survival. Relapse is common following treatment interruption however some patients may be suitable for limited-duration treatment.
Identifiants
pubmed: 37400251
doi: 10.1111/bjh.18964
pmc: PMC10615682
mid: NIHMS1915453
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Fluorodeoxyglucose F18
0Z5B2CJX4D
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-394Subventions
Organisme : NCI NIH HHS
ID : K08 CA218901
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA231804
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA259260
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA254838
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242020
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251138
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA264369
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128239
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Am J Hematol. 2021 May 1;96(5):E146-E150
pubmed: 33539584
Haematologica. 2018 Apr;103(4):e177-e180
pubmed: 29472347
Neuro Oncol. 2020 Jul 7;22(7):979-992
pubmed: 31950179
Nature. 2019 Mar;567(7749):521-524
pubmed: 30867592
JAMA Oncol. 2018 Mar 01;4(3):384-388
pubmed: 29188284
Blood. 2020 May 28;135(22):1929-1945
pubmed: 32187362
Br J Haematol. 2018 Jan;180(1):150-153
pubmed: 27711968
JAMA Oncol. 2022 Dec 1;8(12):1816-1820
pubmed: 36201194
J Natl Compr Canc Netw. 2021 Nov;19(11):1277-1303
pubmed: 34781268
Blood. 2017 Sep 14;130(11):1377-1380
pubmed: 28667012
J Clin Oncol. 2015 Feb 10;33(5):411-8
pubmed: 25422482